Abstract
The present review summarizes the existing literature data regarding the development of newer categories of antidiabetic agents, their mechanism of action and their clinical importance. In this paper, a review of the recent patents for the treatment of diabetes will be presented. In recent years significant achievements have been done, including the development of SGLT2 inhibitors, glucokinase activators as well as the role of free fatty acids and bile acid metabolism in the treatment of diabetes are reviewed.
MeSH terms
-
Animals
-
Benzhydryl Compounds
-
Bile Acids and Salts / antagonists & inhibitors
-
Bile Acids and Salts / biosynthesis
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / metabolism
-
Fatty Acids, Nonesterified / agonists
-
Glucokinase / metabolism
-
Glucosides / adverse effects
-
Glucosides / therapeutic use
-
Humans
-
Hypoglycemic Agents / adverse effects
-
Hypoglycemic Agents / pharmacology
-
Hypoglycemic Agents / therapeutic use*
-
Molecular Targeted Therapy / methods
-
Patents as Topic
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use
-
Sodium-Glucose Transporter 2 Inhibitors*
Substances
-
Benzhydryl Compounds
-
Bile Acids and Salts
-
Fatty Acids, Nonesterified
-
Glucosides
-
Hypoglycemic Agents
-
Pyrazoles
-
Sodium-Glucose Transporter 2 Inhibitors
-
dapagliflozin
-
Glucokinase
-
remogliflozin etabonate